These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 15144871)

  • 1. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease.
    Blandini F; Armentero MT; Fancellu R; Blaugrund E; Nappi G
    Exp Neurol; 2004 Jun; 187(2):455-9. PubMed ID: 15144871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions.
    Truong L; Allbutt H; Kassiou M; Henderson JM
    Behav Brain Res; 2006 Apr; 169(1):1-9. PubMed ID: 16413939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
    Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KDI tripeptide of gamma1 laminin protects rat dopaminergic neurons from 6-OHDA induced toxicity.
    Väänänen AJ; Rauhala P; Tuominen RK; Liesi P
    J Neurosci Res; 2006 Aug; 84(3):655-65. PubMed ID: 16810683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rasagiline enhances L-DOPA-induced contralateral turning in the unilateral 6-hydroxydopamine-lesioned guinea-pig.
    Moses D; Gross A; Finberg JP
    Neuropharmacology; 2004 Jul; 47(1):72-80. PubMed ID: 15165835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy.
    Stefanova N; Poewe W; Wenning GK
    Exp Neurol; 2008 Apr; 210(2):421-7. PubMed ID: 18222424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
    J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
    Saravanan KS; Sindhu KM; Senthilkumar KS; Mohanakumar KP
    Neurochem Int; 2006 Jul; 49(1):28-40. PubMed ID: 16490285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphological and functional effects of PACAP in 6-hydroxydopamine-induced lesion of the substantia nigra in rats.
    Reglodi D; Tamás A; Lubics A; Szalontay L; Lengvári I
    Regul Pept; 2004 Dec; 123(1-3):85-94. PubMed ID: 15518897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low dosage of rasagiline and epigallocatechin gallate synergistically restored the nigrostriatal axis in MPTP-induced parkinsonism.
    Reznichenko L; Kalfon L; Amit T; Youdim MB; Mandel SA
    Neurodegener Dis; 2010; 7(4):219-31. PubMed ID: 20197647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
    Porritt MJ; Batchelor PE; Howells DW
    Exp Neurol; 2005 Mar; 192(1):226-34. PubMed ID: 15698637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effects of intraventricularly administered BMP-7 following a striatal 6-hydroxydopamine lesion.
    Zuch CL; David D; Ujhelyi L; Hudson JL; Gerhardt GA; Kaplan PL; Bickford PC
    Brain Res; 2004 Jun; 1010(1-2):10-6. PubMed ID: 15126112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental parkinsonism in vivo and in vitro.
    Mu X; He G; Cheng Y; Li X; Xu B; Du G
    Pharmacol Biochem Behav; 2009 Jun; 92(4):642-8. PubMed ID: 19327378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Prog Neurobiol; 2010 Nov; 92(3):330-44. PubMed ID: 20600573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotection in Parkinson models varies with toxin administration protocol.
    Anderson DW; Bradbury KA; Schneider JS
    Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystatin C prevents degeneration of rat nigral dopaminergic neurons: in vitro and in vivo studies.
    Xu L; Sheng J; Tang Z; Wu X; Yu Y; Guo H; Shen Y; Zhou C; Paraoan L; Zhou J
    Neurobiol Dis; 2005 Feb; 18(1):152-65. PubMed ID: 15649706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.